SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Article
[키워드] absence
ACE2
acute respiratory syndrome
ADK
antibody
BA.2
BA.5
Beta
BNT162b2
breadth
Breakthrough infection
cell line
change
circulating
clade
Clinical effect
cohorts
contributed
convalescent
convalescent sera
coronavirus
COVID-19
COVID-19 hospitalisation
Delta
development
disease severity
Donor
donors
dose
foundation
Future
genetic difference
greater
humoral
Humoral response
IgG
in vitro
isolate
Lineage
lineages
Live virus
management
monitoring
monoclonal antibody
mortality rates
nafamostat
nasopharyngeal sample
nasopharyngeal swabs
neutralisation
neutralisation assay
Neutralising Antibodies
neutralising antibody
New
observation
of BNT162b2
omicron
Omicron BA.1
other variant
pathway
peak
plasma
potency
recorded
reduced
reduction
reduction in
Research
response
responses
SARS-CoV-2
sensitivity
significantly
Sotrovimab
South
Spread
Support
supported
tested
Testing
therapeutic
Therapies
TMPRSS2
TMPRSS2 inhibitor
Transmission
utilised
vaccination
Vaccine
variant
viral lineage
viral variant
[DOI] 10.1016/j.ebiom.2022.104270 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ebiom.2022.104270 PMC 바로가기 [Article Type] Article